Bullish & Foolish
Full LTRN fundamentals All 466 on the Survival Watch

LTRNLantern Pharma Inc.

Is Lantern Pharma struggling financially?

Yes, by its own account. Lantern Pharma told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector
Biotech/Pharma
Market cap
$29.9M
Source filing
10-Q 15 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 4months

    If the burn speeds up

    Empty by Oct 2026

  • 6months

    If it eases off

    Empty by Dec 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$6.7M

÷

Cash burned over the last 12 months

$15.7M

What Lantern Pharma told the SEC

…uncertainties. The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements relating to: the existence of substantial doubt regarding our ability to continue as a going concern in the absence of obtaining substantial additional funding; our ability to secure sufficient funding and alternative sources of funding to support our existing and proposed…

Lantern Pharma Inc., Form 10-Q, filed 15 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Cash burn is narrowing It is spending 49% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt